The OARS-7 Study for Major Depressive Disorder
The purpose of the J&J OARS-7 Study is to evaluate a medication to treat depression (MDD) and depression with insomnia (MDDIS). This study is for intended for people diagnosed with depression who have only experienced a partial response to their current antidepressant treatment; in other words, they are still currently experiencing symptoms of depression. The main goal of this study is to learn how safe the study drug is and how well the study drug works when taken with the antidepressants you are currently taking for depression.
What will I do if I participate?
There are two parts of this study. In part 1, participants will take part in 8 study visits in-person at Northwestern Hospital where they will be given either study drug or a placebo. After part one, participants may be offered the option to continue into part 2, which is an open-label phase (everyone receives study drug). Visits will include clinical assessments and questionnaires regarding mental health symptoms.
Eligibility Criteria
- Open to ages 18-74.
- Diagnosed with Major Depressive disorder, currently experiencing an episode of depression.
- Must be stable on anti-depressants for 6 weeks, with inadequate improvement.